In the immediate aftermath of the Obamacare rollout, pharma and healthcare M&A fell. Now, however, it's back up, on deals like Monday morning's Covidien - Medtronic announcement, a merger valued at $43 billion. While some deals in the healthcare industry are being guided by synergies, other, like Monday's MergerTalk deal, are being guided by strategy. Medtronic needs to relocate its Minnesota tax base to Ireland, where Covidien is based, in order to save on a hefty U.S. tax bill. Medtronic isn't the only one: Pfizer attempted to acquire AstraZeneca, for the same reasons. The Deal's Jon Marino and Sarah Pringle have details from Wall Street.

If you liked this article you might like

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Mallinckrodt Buys Ikaria in $2.3 Billion Hospital Treatment Deal

Stryker and Smith & Nephew Are the Stars to Watch in Medtech's 2015 Merger Dance

Medtronic Avoids U.S. Taxes While Saddling Shareholders With a Hefty Tax Bill

Trim Positions in Stryker Ahead of Fourth-Quarter Earnings; Buy on Pullback